Vertaling van "succession decisions of development " (Nederlands → Frans) :

Deze informatie, die ook voor diverse doeleinden gebruikt wordt door HR (Performance Management, Succession decisions of Development actions), helpt ons om een beter inzicht te krijgen in uw behoeften en om beter te begrijpen hoe we onze producten en diensten kunnen verbeteren.
Cette information, qui est également utilisée à différentes fins par HR (Performance Management, Succession décisions or Development actions) nous sera utile pour mieux comprendre vos besoins et mieux comprendre comment améliorer nos produits et nos services.

This release contains forward-looking information about an agreement by Pfizer to acquire FoldRx, and about FoldRx’s product candidate tafamidis, its other clinical and preclinical development programs and its technology platform, including their potential benefits, that involves substantial risks and uncertainties. Such risks and uncertainties include, among other things, the satisfaction of conditions to closing the agreement; the uncertainties inherent in research and development; whether and when a new drug application for tafamidis will be filed with the FDA; decisions by regulatory authorities regarding whether and when to approve any drug applications that have been or may be filed for tafamidis and that may be filed for any other product candidates that may be generated by FoldRx’s technology platform as well as their decisions regarding labeling and other matters that could affect the availability or commercial potential of tafamidis and such other product candidates; and competitive developments. A further description of risks and uncertainties can be found in Pfizer’s Annual Report on Form 10-K for the fiscal year ended December 31, 2009 and in its reports on Form 10-Q and Form 8-K.
Such risks and uncertainties include, among other things, the satisfaction of conditions to closing the agreement; the uncertainties inherent in research and development; whether and when a new drug application for tafamidis will be filed with the FDA; decisions by regulatory authorities regarding whether and when to approve any drug applications that have been or may be filed for tafamidis and that may be filed for any other product candidates that may be generated by FoldRx’s technology platform as well as their decisions regarding labeling and other matters that could affect the availability or commercial potential of tafamidis and such other product candidates; and competitive developments.

La requérante a introduit, contre cette décision, un recours qui aboutira au jugement du 11 février 2000. Ce jugement a déclaré le recours fondé et a entériné les conclusions du docteur P. Celui-ci avait considéré que « les modifications successives des lois d'assistance sociale, depuis 1991, constituent un facteur d'aggravation de l'incapacité de la demanderesse à se poser sur le marché de l'emploi ».
P. Celui-ci avait considéré que " les modifications successives des lois d'assistance sociale, depuis 1991, constituent un facteur d'aggravation de l'incapacité de la demanderesse à se poser sur le marché de l'emploi " .

“Comparative cost analysis: Community based services as an alternative to institutions" , tender no. VT/2005/021, Official Journal on 22 June 2005 N° 2005/S 119-117014 [http ...]
K. ; Paul R (Hrsg.) : Health Promoting Hospitals in Practice: Developing Projects and Networks – Conrad, Gamburg Inclusion Europe, Included in Society (2003-2004), projet réalisé dans le contexte du Fonds social européen ( [http ...]

Such risks and uncertainties include, among other things, the uncertainties inherent in research and development; whether and when regulatory authorities in countries where regulatory applications for Prevenar 13 may be pending or may be submitted will approve such applications and their decisions regarding labeling and other matters that could affect its availability or commercial potential; and competitive developments.
This release contains forward-looking information that involves substantial risks and uncertainties regarding Prevenar 13, including its potential benefits; and the success of the AMC project for vaccines. Such risks and uncertainties include, among other things, the uncertainties inherent in research and development; whether and when regulatory authorities in countries where regulatory applications for Prevenar 13 may be pending or may be submitted will approve such applications and their decisions regarding labeling and other matters that could affect its availability or commercial potential; and competitive developments. A further description of risks and uncertainties can be found in Pfizer’s Annual Report on Form 10-K for the fiscal year ended December 31, 2009, and in its reports on Form 10-Q and Form 8-K.

The implementation of the new organisation chart as envisaged for the start of 2009 requires the P&O Service to develop a definition of its future role in terms of the expectations from the 3 Directorates-General and other departments and services, to implement the 1 % reduction imposed for personnel expenditure and to further develop the strategic decision to convert the FAMHP into a “learning organisation”.
The implementation of the new organisation chart as envisaged for the start of 2009 requires the P&O Service to develop a definition of its future role in terms of the expectations from the 3 Directorates-General and other departments and services, to implement the 1 % reduction imposed for personnel expenditure and to further develop the strategic decision to convert the FAMHP into a “learning organisation”.

Delivering innovation, growth and productivity The success of Novartis is driven by a commitment to three strategic priorities: (1) extending our lead in innovation through the research and development of differentiated new medicines, vaccines and diagnostics; (2) accelerating growth across all divisions by broadening our product portfolios with new launches and increasing our presence in new markets; and (3) improving profitability through productivity by streamlining and simplifying our processes.
Promouvoir l'innovation, la croissance et la productivité Le succès de Novartis est porté par son engagement envers trois priorités stratégiques: Augmenter notre avance dans l’innovation en recherchant et développant de nouveaux médicaments, vaccins et diagnostics différenciés, 2) accélérer notre croissance dans toutes les divisions en élargissant notre portefeuille par le lancement de nouveaux de produits et en accroissant notre présence dans de nouveaux marchés et 3) améliorer notre profitabilité par le biais de la productivité en rationalisant et en simplifiant nos processus.

Compliance with the European directives on electronic submissions Compliance with the European directives requires a number of objectives to be achieved: ●● Arriving at a functional vision of communication standards with EMEA and the Member States in partnership with the industry and in line with European legislation ●● Standard project management, with important steps that are sponsored/supported by the Member States: first developing an IT infrastructure and then starting on a highly secure network followed by so-called “proofs of concept” in each field ●● Success depends above all on the FAHMP’s
Compliance with the European directives on electronic submissions Compliance with the European directives requires a number of objectives to be achieved: ●● Arriving at a functional vision of communication standards with EMEA and the Member States in partnership with the industry and in line with European legislation ●● Standard project management, with important steps that are sponsored/supported by the Member States: first developing an IT infrastructure and then starting on a highly secure network followed by so-called “proofs of concept” in each field ●● Success depends above all on the FAHMP’s

The role of the Central Working Group is to take decisions together with the Chief Executive Officer regarding the development of the FAMHP and to set priorities.
The role of the Central Working Group is to take decisions together with the Chief Executive Officer regarding the development of the FAMHP and to set priorities.